Ziegler Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Ziegler Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-31,806	Closed	-$235K	–	423
2022 Q4	$235K	Sell	31,806 -7,419	-19%	-$72.3K	0.01%	380
2022 Q3	$388K	Sell	39,225 -229	-0.6%	-$2.42K	0.02%	355
2022 Q2	$430K	Buy	39,454 +1,016	+3%	+$10.5K	0.02%	352
2022 Q1	$435K	Sell	38,438 -3,200	-8%	-$42.1K	0.02%	337
2021 Q4	$653K	Sell	41,638 -13,568	-25%	-$236K	0.02%	353
2021 Q3	$946K	Sell	55,206 -1,880	-3%	-$32.9K	0.03%	334
2021 Q2	$1.23M	Buy	57,086 +1,678	+3%	+$30K	0.04%	320
2021 Q1	$832K	Sell	55,408 -1,467	-3%	-$23.7K	0.03%	351
2020 Q4	$747K	Buy	+56,875	New	+$685K	0.02%	354

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ziegler Capital Management's VNDA Position: Q1 2023 in Review

Ziegler Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 31,806 shares — an estimated $235K sold.

Ziegler Capital Management first reported a position in VNDA in Q4 2020 and held it in 9 quarters. The position peaked at $1.23M in Q2 2021. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Ziegler Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ziegler Capital Management sold 31,806 Vanda Pharmaceuticals shares in Q1 2023, an estimated $235K.
Ziegler Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Ziegler Capital Management's Vanda Pharmaceuticals position peaked at $1.23M in Q2 2021.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Ziegler Capital Management's 13F filing for Q1 2023, filed 4 May 2023.